Search
deucravacitinib (Sotyktu)
Indications:
- moderate to severe plaque psoriasis
Contraindications:
- avoid use with live virus vaccines
Dosage:
- 6 mg PO QD
Monitor:
- serum triglycerides baseline & periodically
- liver function tests baseline & periodically
Adverse effects:
- hypersensitivity reactions
- infactions including tuberculosis
- lymphomas
- elevated serum creatine kinase & rhabdomyolysis
- hypertriglyceridemia
- elevated serum ALT, serum AST
Mechanism of action:
- tyrosine kinase-2 inhibitor (TYK2 inhibitor) thar inhibits signaling of IL-23, IL-12, & IFN-1, cytokines involved in the pathogenesis of autoimmune diseases [2]
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
Janus kinase inhibitor; JAK inhibitor
dermatologic agent
References
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Sotyktu (deucravacitinib) tablets, for oral use
https://packageinserts.bms.com/pi/pi_sotyktu.pdf
- Splete H
FDA Approves Oral TYK2 Inhibitor Deucravacitinib for Treating Psoriasis.
Medscsape. Sept 12, 2022
https://www.medscape.com/viewarticle/980551